CL2016001441A1 - Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. - Google Patents
Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes.Info
- Publication number
- CL2016001441A1 CL2016001441A1 CL2016001441A CL2016001441A CL2016001441A1 CL 2016001441 A1 CL2016001441 A1 CL 2016001441A1 CL 2016001441 A CL2016001441 A CL 2016001441A CL 2016001441 A CL2016001441 A CL 2016001441A CL 2016001441 A1 CL2016001441 A1 CL 2016001441A1
- Authority
- CL
- Chile
- Prior art keywords
- ror
- disorders
- useful
- treatment
- 1hpyrrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (i) y sales farmacéuticamente aceptables de los mismos, en la cual x, x1, m, r2, r3, r4, r5, m, n, y p son como se definen en la presente, los cuales son activos como moduladores del receptor gamma t huérfano (ror?t) relacionado con retinoides. estos compuestos previenen, inhibir, o suprimen la acción de ror?t y por lo tanto son útiles en el tratamiento de enfermedades, trastornos, síndromes o afecciones mediados por ror?t tales como, por ejemplo, d
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3853MU2013 | 2013-12-10 | ||
IN527MU2014 | 2014-02-14 | ||
IN2172MU2014 | 2014-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001441A1 true CL2016001441A1 (es) | 2017-03-03 |
Family
ID=52355020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001441A CL2016001441A1 (es) | 2013-12-10 | 2016-06-10 | Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9682977B2 (es) |
EP (1) | EP3080090B1 (es) |
JP (1) | JP2016539989A (es) |
CN (1) | CN105980364A (es) |
AP (1) | AP2016009281A0 (es) |
AU (1) | AU2014363035A1 (es) |
BR (1) | BR112016013425A2 (es) |
CA (1) | CA2933003A1 (es) |
CL (1) | CL2016001441A1 (es) |
EA (1) | EA029489B1 (es) |
IL (1) | IL246123A0 (es) |
MX (1) | MX2016007604A (es) |
PE (1) | PE20160687A1 (es) |
PH (1) | PH12016501105A1 (es) |
SG (1) | SG11201604714SA (es) |
TW (1) | TW201605797A (es) |
WO (1) | WO2015087234A1 (es) |
ZA (1) | ZA201604454B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201419015D0 (en) | 2014-10-24 | 2014-12-10 | Orca Pharmaceuticals Ltd | Compounds |
WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
WO2017051319A1 (en) * | 2015-09-21 | 2017-03-30 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl ether compounds as ror gamma modulators |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
UY37507A (es) | 2016-12-05 | 2018-06-29 | Lead Pharma Holding Bv | Moduladores de ror gamma (ror¿) |
BR112019026945A2 (pt) * | 2017-07-06 | 2020-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | derivado de indol-formamida, método de preparação para ele e seu uso em medicina |
US11466024B2 (en) | 2017-08-01 | 2022-10-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicylic compound acting as an inhibitor |
WO2019100106A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Sydney | Antibacterial compounds and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200621237A (en) * | 2004-11-01 | 2006-07-01 | Wyeth Corp | [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones |
EP1837329A4 (en) | 2005-01-14 | 2009-08-05 | Dainippon Sumitomo Pharma Co | NEW HETEROARYL DERIVATIVE |
WO2012024620A2 (en) * | 2010-08-20 | 2012-02-23 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
EP2638014B1 (en) * | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
EP2511263A1 (en) | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
-
2014
- 2014-11-26 TW TW103140995A patent/TW201605797A/zh unknown
- 2014-12-09 AP AP2016009281A patent/AP2016009281A0/en unknown
- 2014-12-09 JP JP2016538031A patent/JP2016539989A/ja active Pending
- 2014-12-09 US US15/103,658 patent/US9682977B2/en not_active Expired - Fee Related
- 2014-12-09 CA CA2933003A patent/CA2933003A1/en not_active Abandoned
- 2014-12-09 EP EP14827867.4A patent/EP3080090B1/en not_active Not-in-force
- 2014-12-09 BR BR112016013425A patent/BR112016013425A2/pt active Search and Examination
- 2014-12-09 PE PE2016000783A patent/PE20160687A1/es not_active Application Discontinuation
- 2014-12-09 EA EA201691002A patent/EA029489B1/ru not_active IP Right Cessation
- 2014-12-09 SG SG11201604714SA patent/SG11201604714SA/en unknown
- 2014-12-09 MX MX2016007604A patent/MX2016007604A/es unknown
- 2014-12-09 AU AU2014363035A patent/AU2014363035A1/en not_active Abandoned
- 2014-12-09 WO PCT/IB2014/066720 patent/WO2015087234A1/en active Application Filing
- 2014-12-09 CN CN201480074962.XA patent/CN105980364A/zh active Pending
-
2016
- 2016-06-08 IL IL246123A patent/IL246123A0/en unknown
- 2016-06-09 PH PH12016501105A patent/PH12016501105A1/en unknown
- 2016-06-10 ZA ZA2016/04454A patent/ZA201604454B/en unknown
- 2016-06-10 CL CL2016001441A patent/CL2016001441A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016539989A (ja) | 2016-12-22 |
AP2016009281A0 (en) | 2016-06-30 |
WO2015087234A1 (en) | 2015-06-18 |
CA2933003A1 (en) | 2015-06-18 |
AU2014363035A1 (en) | 2016-06-30 |
US20160326163A1 (en) | 2016-11-10 |
US9682977B2 (en) | 2017-06-20 |
MX2016007604A (es) | 2017-02-28 |
ZA201604454B (en) | 2017-11-29 |
EA201691002A1 (ru) | 2016-12-30 |
SG11201604714SA (en) | 2016-07-28 |
CN105980364A (zh) | 2016-09-28 |
TW201605797A (zh) | 2016-02-16 |
BR112016013425A2 (pt) | 2017-08-08 |
IL246123A0 (en) | 2016-08-02 |
EP3080090A1 (en) | 2016-10-19 |
EP3080090B1 (en) | 2018-01-31 |
EA029489B1 (ru) | 2018-04-30 |
PH12016501105A1 (en) | 2016-07-11 |
PE20160687A1 (es) | 2016-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001441A1 (es) | Compuestos derivados de 1h-indol, 1h-indazol, 1hpirrolo-[2,3-b]-piridin, 1h-pirazolo-[3,4-b]-piridin, moduladores de ror; composición farmacéutica; útiles para el tratamiento de una enfermedad, trastornos o síndrome mediado por ror?t, tales como enfermedades inflamatorias o autoinmunes. | |
MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
MX2019007474A (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
MX2016013046A (es) | Compuestos organicos. | |
MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
CR20180185A (es) | Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales | |
CO2018002063A2 (es) | Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
CL2018000292A1 (es) | Compuestos farmacéuticos | |
CU20170154A7 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk | |
CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
CU20150056A7 (es) | Derivados e 1h- bencimidazol como antagonistas de ep4 y medicamentos que los contienen | |
CO2017001152A2 (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock) | |
CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
MX2014012374A (es) | Compuestos organicos. | |
CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
CL2018000289A1 (es) | Compuestos nuevos como moduladores de ror gamma. | |
CL2013001772A1 (es) | Compuestos derivados de indol y azaindol, como inhibidores de la faah; composicion farmaceutica que los comprende, util para el tratamiento o prevencion del dolor, trastornos autoinmunes, procesos inflamatorios, enfermedades gastrointestinales, prurito, enfermedad relacionada con abuso de sustancias, entre otras enfermedades. | |
CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
CL2017002799A1 (es) | Sulfonas triciclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rory) | |
DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
CR20160574A (es) | Compuestos de dihidroisoquinolinona sustituida | |
UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
EA201692037A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет |